These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 27780333)

  • 21. Incidence and predictors of acute akathisia in severely ill patients with first-episode schizophrenia treated with aripiprazole or risperidone: secondary analysis of an observational study.
    Yoshimura B; Sato K; Sakamoto S; Tsukahara M; Yoshimura Y; So R
    Psychopharmacology (Berl); 2019 Feb; 236(2):723-730. PubMed ID: 30443794
    [TBL] [Abstract][Full Text] [Related]  

  • 22. No Differences in Weight Gain Between Risperidone and Aripiprazole in Children and Adolescents After 12 Months.
    Schoemakers RJ; van Kesteren C; van Rosmalen J; Eussen MLJM; Dieleman HG; Beex-Oosterhuis MM
    J Child Adolesc Psychopharmacol; 2019 Apr; 29(3):192-196. PubMed ID: 30672720
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Switching to aripiprazole in outpatients with schizophrenia experiencing insufficient efficacy and/or safety/tolerability issues with risperidone: a randomized, multicentre, open-label study.
    Ryckmans V; Kahn JP; Modell S; Werner C; McQuade RD; Kerselaers W; Lissens J; Sanchez R
    Pharmacopsychiatry; 2009 May; 42(3):114-21. PubMed ID: 19452380
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of second-generation antipsychotics with acute-phase schizophrenia.
    Hatta K; Sato K; Hamakawa H; Takebayashi H; Kimura N; Ochi S; Sudo Y; Asukai N; Nakamura H; Usui C; Kawabata T; Hirata T; Sawa Y
    Schizophr Res; 2009 Aug; 113(1):49-55. PubMed ID: 19553086
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence of cardiovascular outcomes and diabetes mellitus among users of second-generation antipsychotics.
    Citrome L; Collins JM; Nordstrom BL; Rosen EJ; Baker R; Nadkarni A; Kalsekar I
    J Clin Psychiatry; 2013 Dec; 74(12):1199-206. PubMed ID: 24434088
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
    Dossenbach M; Erol A; el Mahfoud Kessaci M; Shaheen MO; Sunbol MM; Boland J; Hodge A; O'Halloran RA; Bitter I;
    J Clin Psychiatry; 2004 Mar; 65(3):312-21. PubMed ID: 15096069
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antipsychotic Treatment Duration in Children and Adolescents: A Register-Based Nationwide Study.
    Varimo E; Aronen ET; Mogk H; Rättö H; Saastamoinen LK
    J Child Adolesc Psychopharmacol; 2021 Aug; 31(6):421-429. PubMed ID: 33739863
    [No Abstract]   [Full Text] [Related]  

  • 28. Confounding by indication of a specific antipsychotic and the increase of body mass index among children and adolescents.
    Martínez-Ortega JM; Diaz-Atienza F; Gutiérrez-Rojas L; Jurado D; Gurpegui M
    Eur Child Adolesc Psychiatry; 2011 Dec; 20(11-12):597-8. PubMed ID: 21927910
    [No Abstract]   [Full Text] [Related]  

  • 29. Increased Risk of Obesity and Metabolic Dysregulation Following 12 Months of Second-Generation Antipsychotic Treatment in Children: A Prospective Cohort Study.
    Ronsley R; Nguyen D; Davidson J; Panagiotopoulos C
    Can J Psychiatry; 2015 Oct; 60(10):441-50. PubMed ID: 26720191
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk of arrest in persons with schizophrenia and bipolar disorder in a Florida Medicaid program: the role of atypical antipsychotics, conventional neuroleptics, and routine outpatient behavioral health services.
    Van Dorn RA; Andel R; Boaz TL; Desmarais SL; Chandler K; Becker MA; Howe A
    J Clin Psychiatry; 2011 Apr; 72(4):502-8. PubMed ID: 21527125
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacotherapy of Autism Spectrum Disorder: Results from the Randomized BAART Clinical Trial.
    DeVane CL; Charles JM; Abramson RK; Williams JE; Carpenter LA; Raven S; Gwynette F; Stuck CA; Geesey ME; Bradley C; Donovan JL; Hall AG; Sherk ST; Powers NR; Spratt E; Kinsman A; Kruesi MJ; Bragg JE
    Pharmacotherapy; 2019 Jun; 39(6):626-635. PubMed ID: 31063671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.
    Schneider LS; Tariot PN; Dagerman KS; Davis SM; Hsiao JK; Ismail MS; Lebowitz BD; Lyketsos CG; Ryan JM; Stroup TS; Sultzer DL; Weintraub D; Lieberman JA;
    N Engl J Med; 2006 Oct; 355(15):1525-38. PubMed ID: 17035647
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Aripiprazole versus risperidone for treating children and adolescents with tic disorder: a randomized double blind clinical trial.
    Ghanizadeh A; Haghighi A
    Child Psychiatry Hum Dev; 2014 Oct; 45(5):596-603. PubMed ID: 24343476
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcome of Youth with Early-Phase Schizophrenia-Spectrum Disorders and Psychosis Not Otherwise Specified Treated with Second-Generation Antipsychotics: 12 Week Results from a Prospective, Naturalistic Cohort Study.
    Vernal DL; Kapoor S; Al-Jadiri A; Sheridan EM; Borenstein Y; Mormando C; David L; Singh S; Seidman AJ; Carbon M; Gerstenberg M; Saito E; Kane JM; Steinhausen HC; Correll CU
    J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):535-47. PubMed ID: 26375767
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic antipsychotic treatment differentially modulates protein kinase A- and glycogen synthase kinase 3 beta-dependent signaling pathways, N-methyl-D-aspartate receptor and γ-aminobutyric acid A receptors in nucleus accumbens of juvenile rats.
    Pan B; Lian J; Deng C
    J Psychopharmacol; 2018 Nov; 32(11):1252-1263. PubMed ID: 30136620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-Acting Injectable Atypical Antipsychotic Use in Adolescents: An Observational Study.
    Fortea A; Ilzarbe D; Espinosa L; Solerdelcoll M; de Castro C; Oriolo G; Sugranyes G; Baeza I
    J Child Adolesc Psychopharmacol; 2018 May; 28(4):252-257. PubMed ID: 29381388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities.
    Valicenti-McDermott MR; Demb H
    J Child Adolesc Psychopharmacol; 2006 Oct; 16(5):549-60. PubMed ID: 17069544
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Time to discontinuation and self-discontinuation of olanzapine and risperidone in patients with schizophrenia in a naturalistic outpatient setting.
    Kilzieh N; Todd-Stenberg JA; Kennedy A; Wood AE; Tapp AM
    J Clin Psychopharmacol; 2008 Feb; 28(1):74-7. PubMed ID: 18204345
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents.
    Findling RL
    J Clin Psychiatry; 2008; 69 Suppl 4():9-14. PubMed ID: 18533763
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early Stabilization of Weight Changes Following Treatment With Olanzapine, Risperidone, and Aripiprazole: A 12-Month Naturalistic Study of First Episode Psychosis.
    Mustafa S; Joober R; Iyer S; Shah J; Lepage M; Malla A
    J Clin Psychiatry; 2019 Aug; 80(5):. PubMed ID: 31509359
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.